BECONASE Drug Patent Profile

When do Beconase patents expire, and when can generic versions of Beconase launch?

Beconase is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in BECONASE is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.

Summary for BECONASE

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	4
Patent Applications:	4,697
Drug Prices:	Drug price information for BECONASE
What excipients (inactive ingredients) are in BECONASE?	BECONASE excipients list
DailyMed Link:	BECONASE at DailyMed

See drug prices for BECONASE

Recent Clinical Trials for BECONASE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
West Penn Allegheny Health System	Phase 4
University Health Network, Toronto	N/A
Glaucoma Research Society of Canada	N/A

See all BECONASE clinical trials

US Patents and Regulatory Information for BECONASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BECONASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018584-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Glaxosmithkline	BECONASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019389-001	Jul 27, 1987		DISCN	Yes	No

Expired US Patents for BECONASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	BECONASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018584-001	Approved Prior to Jan 1, 1982
Glaxosmithkline	BECONASE	beclomethasone dipropionate	AEROSOL, METERED;NASAL	018584-001	Approved Prior to Jan 1, 1982

International Patents for BECONASE

See the table below for patents covering BECONASE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	134923
Austria	A302275
United Kingdom	1429184
Germany	7537646
Netherlands	7305438
Austria	A352973
Argentina	196524	UN METODO PARA CONVERTIR UN ESTEROIDE A UNA FORMA QUE NO EXHIBE CRISTALINO EN PROPULSORES DE AEROSOL

BECONASE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Beconase

Introduction to Beconase

Beconase, a brand name for the active ingredient beclomethasone dipropionate, is a synthetic corticosteroid used primarily to treat allergic rhinitis and other respiratory conditions such as asthma. Understanding the market dynamics and financial trajectory of Beconase involves analyzing various factors including market size, growth drivers, regional performance, and the financial health of key players in the industry.

Market Size and Growth

The Beconase market, or more broadly the beclomethasone dipropionate market, is experiencing moderate growth. This growth is driven by several key factors:

• Increasing Population and Asthma Prevalence: The global population is growing, and so is the number of people suffering from asthma and allergic rhinitis. This increase in patient numbers is a significant driver for the market[4].
• Advancements in Technology: Continuous advancements in pharmaceutical technologies and formulations are enhancing the efficacy and delivery methods of beclomethasone dipropionate, making it more appealing to consumers[4].
• Changing Lifestyle and Disposable Income: As people's lifestyles change and disposable incomes increase, there is a greater demand for effective treatments for respiratory conditions[4].

Regional Performance

The market for beclomethasone dipropionate is segmented geographically into several key regions:

• North America: This region holds a significant share of the market due to the high prevalence of asthma and allergic rhinitis, as well as a strong healthcare infrastructure[4].
• Europe: Countries like Germany, the UK, and France contribute substantially to the European market, driven by similar factors as North America[4].
• Asia Pacific: This region is growing rapidly due to increasing awareness and access to healthcare, particularly in countries like China, Japan, and India[4].
• Rest of the World: Latin America and the Middle East & Africa also contribute to the market growth, albeit at a slower pace compared to other regions[4].

Key Players and Financial Performance

Several pharmaceutical companies are key players in the beclomethasone dipropionate market:

• Perrigo: Perrigo, a company that produces a range of healthcare products including those under the Consumer Self-Care International (CSCI) segment, has shown significant financial improvements. For instance, in fiscal year 2023, Perrigo reported a gross margin improvement of 340 basis points to 36.1%, and adjusted gross margin of 38.8%. The company's adjusted diluted EPS increased by 24.6% compared to the prior year, driven by gross profit flow-through and cost synergies from acquisitions[2].
• GlaxoSmithKline (GSK): Although GSK's financial reports do not specifically highlight Beconase, the company's broad portfolio of pharmaceutical products and its focus on respiratory diseases indicate a strong presence in this market. GSK's financial performance in 2004, for example, showed a one percent increase in global pharmaceutical sales despite generic competition, highlighting the company's resilience and adaptability[3].

Market Trends and Drivers

Increasing Demand for Respiratory Treatments

The rising prevalence of respiratory conditions such as asthma and allergic rhinitis is a primary driver for the Beconase market. Industrialization and urbanization have increased exposure to allergens and pollutants, contributing to this trend[4].

Technological Advancements

Advancements in drug delivery systems, such as intranasal sprays and inhalers, have improved the efficacy and user experience of beclomethasone dipropionate. These innovations are attracting more consumers and driving market growth[4].

Regulatory Environment

Regulatory approvals and compliance play a crucial role in the pharmaceutical industry. Companies must navigate complex regulatory landscapes to bring new formulations and delivery methods to market. For instance, any changes in FDA regulations can significantly impact the market trajectory of drugs like Beconase[3].

Restraints and Challenges

Side Effects and Safety Concerns

Beclomethasone dipropionate, like other corticosteroids, comes with potential side effects such as nasal dryness, irritation, and in rare cases, more serious conditions. These safety concerns can act as a barrier to market growth[4].

Generic Competition

The entry of generic versions of beclomethasone dipropionate can reduce the market share of branded products like Beconase. Generic competition can lead to price erosion and reduced profitability for original manufacturers[3].

Financial Trajectory

Revenue Growth

The beclomethasone dipropionate market is expected to grow significantly over the forecast period, driven by increasing demand and technological advancements. The market size is projected to expand at a moderate pace, with substantial growth rates anticipated from 2025 to 2031[1][4].

Gross Margin and Operating Income

Companies like Perrigo have reported improvements in gross margins and operating income, partly due to strategic pricing actions, favorable volume/mix, and the integration of higher-margin acquisitions. These financial metrics indicate a positive trajectory for companies involved in the Beconase market[2][5].

Competitive Landscape

The competitive landscape of the beclomethasone dipropionate market is characterized by several key players:

• AMRI
• Avik Pharmaceutical Ltd.
• Anuh Pharma Ltd
• Cipla Inc.
• Teva Pharmaceutical Industries Ltd.

These companies are engaged in various strategies such as product innovation, strategic pricing, and acquisitions to maintain and expand their market share[4].

Consumer Behavior Analysis

Consumer behavior plays a crucial role in the pharmaceutical market. Increasing awareness about respiratory health and the availability of effective treatments are driving consumer demand for products like Beconase. Additionally, the rise in disposable income and changes in lifestyle are contributing to the growing demand for these medications[1].

Key Takeaways

• The Beconase market is driven by increasing prevalence of respiratory conditions and technological advancements.
• Key players like Perrigo and GSK are experiencing financial improvements due to strategic actions and market demand.
• The market faces challenges from generic competition and safety concerns.
• Regional performance varies, with North America and Europe being significant markets.
• Consumer behavior and regulatory environments are critical factors influencing market dynamics.

FAQs

What is Beconase used for?

Beconase is used primarily to treat allergic rhinitis and other respiratory conditions such as asthma.

Which regions are the largest markets for Beconase?

North America and Europe are the largest markets for Beconase, followed by the Asia Pacific region.

What are the key drivers for the Beconase market?

The key drivers include the increasing prevalence of respiratory conditions, technological advancements, and changes in lifestyle and disposable income.

What are the potential restraints for the Beconase market?

Potential restraints include side effects and safety concerns, as well as generic competition.

Which companies are key players in the Beconase market?

Key players include Perrigo, GlaxoSmithKline, AMRI, Avik Pharmaceutical Ltd., Anuh Pharma Ltd, Cipla Inc., and Teva Pharmaceutical Industries Ltd.

Sources

1. Global Beconase Market Report 2024 Edition - Cognitivemarketresearch.com
2. Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results - Prnewswire.com
3. GlaxoSmithKline 2003 Growth 2004 (restated) Statutory results - GSK.com
4. Beclomethasone Dipropionate Market Size, Share, Trends & Forecast - Verifiedmarketresearch.com
5. Perrigo Reports First Quarter Fiscal Year 2023 Financial Results - Biospace.com